Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya

Autor: Winnie Chebore, Zhiyong Zhou, Nelli Westercamp, Kephas Otieno, Ya Ping Shi, Sheila B. Sergent, Kelsey Anne Rondini, Samaly Souza Svigel, Benard Guyah, Venkatachalam Udhayakumar, Eric S. Halsey, Aaron M. Samuels, Simon Kariuki
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Malaria Journal, Vol 19, Iss 1, Pp 1-12 (2020)
Druh dokumentu: article
ISSN: 1475-2875
DOI: 10.1186/s12936-020-03358-7
Popis: Abstract Background Anti-malarial drug resistance remains a major threat to global malaria control efforts. In Africa, Plasmodium falciparum remains susceptible to artemisinin-based combination therapy (ACT), but the emergence of resistant parasites in multiple countries in Southeast Asia and concerns over emergence and/or spread of resistant parasites in Africa warrants continuous monitoring. The World Health Organization recommends that surveillance for molecular markers of resistance be included within therapeutic efficacy studies (TES). The current study assessed molecular markers associated with resistance to Artemether−lumefantrine (AL) and Dihydroartemisinin−piperaquine (DP) from samples collected from children aged 6–59 months enrolled in a TES conducted in Siaya County, western Kenya from 2016 to 2017. Methods Three hundred and twenty-three samples collected pre-treatment (day-0) and 110 samples collected at the day of recurrent parasitaemia (up to day 42) were tested for the presence of drug resistance markers in the Pfk13 propeller domain, and the Pfmdr1 and Pfcrt genes by Sanger sequencing. Additionally, the Pfpm2 gene copy number was assessed by real-time polymerase chain reaction. Results No mutations previously associated with artemisinin resistance were detected in the Pfk13 propeller region. However, other non-synonymous mutations in the Pfk13 propeller region were detected. The most common mutation found on day-0 and at day of recurrence in the Pfmdr1 multidrug resistance marker was at codon 184F. Very few mutations were found in the Pfcrt marker (
Databáze: Directory of Open Access Journals